MR 101
Alternative Names: MR-101Latest Information Update: 05 Dec 2022
At a glance
- Originator Shinkei Therapeutics
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Movement disorders
Most Recent Events
- 23 Nov 2022 MR 101 is available for licensing as of 23 Nov 2022. https://shinkeitherapeutics.com/development.php
- 23 Nov 2022 Preclinical trials in Movement disorders in USA (unspecified route) (SHINKEI Therapeutics pipeline, November 2022)
- 23 Nov 2022 SHINKEI Therapeutics plans a phase I trial for Movement disorders, in early 2022 (SHINKEI Therapeutics pipeline, November 2022)